Number of items: 6.
2021
Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K.
(2021)
The implications of CAR-T cell therapy on apheresis services: a Scottish perspective.
Journal of Clinical Apheresis, 36(3),
pp. 513-515.
(doi: 10.1002/jca.21871)
(PMID:33378123)
Latif, A.-L. et al.
(2021)
BRD4-mediated repression of p53 is a target for combination therapy in AML.
Nature Communications, 12,
241.
(doi: 10.1038/s41467-020-20378-8)
(PMID:33431824)
(PMCID:PMC7801601)
2020
Horne, G. et al.
(2020)
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Leukemia, 34(7),
pp. 1775-1786.
(doi: 10.1038/s41375-019-0700-9)
(PMID:31925317)
(PMCID:PMC7224085)
2016
Latif, A.-L. and Holyoake, T.
(2016)
Lifting the differentiation embargo.
Cell, 167(1),
pp. 45-46.
(doi: 10.1016/j.cell.2016.08.051)
(PMID:27662083)
2015
Latif, A.-L., Cole, J. J., Monteiro Campos, J., Clark, W., McGarry, L., Brock, C., Newcombe, A., Keeshan, K. , Copland, M. and Adams, P. D.
(2015)
Dual inhibition of MDM2 and BET cooperate to eradicate acute myeloid leukemia.
Blood, 126(23),
p. 674.
(doi: 10.1182/blood.V126.23.674.674)
2013
Sinclair, A., Latif, A.L. and Holyoake, T.L.
(2013)
Targeting survival pathways in chronic myeloid leukaemia stem cells.
British Journal of Pharmacology, 169(8),
pp. 1693-1707.
(doi: 10.1111/bph.12183)
This list was generated on Sat Aug 17 07:53:48 2024 BST.